This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Leishmaniasis	Pteridine reductase (PTR1); dihydrofolate reductase (DHFR)	<i>In vitro</i> studies identified antifolate inhibitors of <i>Leishmania major</i> Ptr1 that could be used with Dhfr inhibitors to help treat parasitic infection. In cultured <i>L. major</i> , five Ptr1-targeting compounds showed efficacy against the parasite in combination with the Dhfr inhibitor pyrimethamine. One of the Ptr1-targeting compounds also showed efficacy as monotherapy. Ongoing studies include developing compounds to use in tandem with the inhibitors. SciBX 4(2); doi:10.1038/scibx.2011.47 Published online Jan. 13, 2011	Patent application filed in Italy for use of the inhibitors to prevent and treat parasitic infections; available for licensing	Ferrari, S. <i>et al.</i> <i>J. Med. Chem.</i> ; published online Dec. 2, 2010; doi:10.1021/jm1010572 Contact: M. Paola Costi, University of Modena and Reggio Emilia, Modena, Italy e-mail: mariapaola.costi@unimore.it Contact: Rebecca C. Wade, Heidelberg Institute for Theoretical Studies gGmbH, Heidelberg, Germany e-mail: rebecca.wade@h-its.org